BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30371331)

  • 1. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
    J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.
    Fu EL; Clase CM; Evans M; Lindholm B; Rotmans JI; Dekker FW; van Diepen M; Carrero JJ
    Am J Kidney Dis; 2021 May; 77(5):719-729.e1. PubMed ID: 33246024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
    Chang TI; Zheng Y; Montez-Rath ME; Winkelmayer WC
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1401-1412. PubMed ID: 27354656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury.
    Brar S; Liu KD; Go AS; Hsu RK; Chinchilli VM; Coca SG; Garg AX; Himmelfarb J; Ikizler TA; Kaufman J; Kimmel PL; Parikh CR; Siew ED; Ware LB; Zeng H; Hsu CY; ;
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):26-36. PubMed ID: 33272913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
    Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
    Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
    Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1129-1138. PubMed ID: 32675281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
    Schroeder EB; Chonchol M; Shetterly SM; Powers JD; Adams JL; Schmittdiel JA; Nichols GA; O'Connor PJ; Steiner JF
    Clin J Am Soc Nephrol; 2018 May; 13(5):727-734. PubMed ID: 29572286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.
    Magvanjav O; Cooper-DeHoff RM; McDonough CW; Gong Y; Segal MS; Hogan WR; Johnson JA
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):91-101. PubMed ID: 30427124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.
    Akhabue E; Vu TT; Vaidya A; Michos ED; de Boer IH; Kestenbaum B; Allison M; Szklo M; Ouyang P; Yancy CW; Wolf M; Isakova T; Carnethon MR
    Am J Hypertens; 2019 Jan; 32(1):18-25. PubMed ID: 30256890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the United States: a cross-sectional analysis of the national health and nutrition examination survey.
    Sonawane KB; Qian J; Hansen RA
    Clin Ther; 2015 Jan; 37(1):188-96. PubMed ID: 25524390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
    Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
    Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.
    Lin YC; Lin JW; Wu MS; Chen KC; Peng CC; Kang YN
    PLoS One; 2017; 12(12):e0188975. PubMed ID: 29240784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
    Salvador GL; Marmentini VM; Cosmo WR; Junior EL
    Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.